Effectiveness of COVID-19 vaccination against COVID-19 specific and all-cause mortality in older Australians: a population based study

被引:12
|
作者
Liu, Bette [1 ,2 ]
Stepien, Sandrine [1 ]
Dobbins, Timothy [2 ,3 ]
Gidding, Heather [1 ,2 ,9 ]
Henry, David [2 ,3 ,4 ]
Korda, Rosemary [5 ]
Mills, Lucas [6 ]
Pearson, Sallie-Anne [2 ,3 ]
Pratt, Nicole [3 ,7 ]
Vajdic, Claire M. [3 ,8 ]
Welsh, Jennifer [5 ]
Macartney, Kristine [1 ,9 ]
机构
[1] Natl Ctr Immunisat Res & Surveillance, Westmead, Australia
[2] UNSW Sydney, Sch Populat Hlth, Kensington, Australia
[3] NHMRC Med Intelligence Ctr Res Excellence, Sydney, Australia
[4] Bond Univ, Inst Evidence Based Healthcare, Robina, Australia
[5] Australian Natl Univ, Natl Ctr Epidemiol & Populat Hlth, Canberra, Australia
[6] Commonwealth Govt Australia, Dept Hlth & Aged Care, Canberra, Australia
[7] Univ South Australia, Qual Use Med & Pharm Res Ctr, Clin & Hlth Sci, Adelaide, Australia
[8] UNSW Sydney, Kirby Inst, Kensington, Australia
[9] Univ Sydney, Fac Med & Hlth, Camperdown, Australia
来源
关键词
COVID-19; Vaccine effectiveness; Mortality; Waning effectiveness; INFECTION; DURATION; OMICRON;
D O I
10.1016/j.lanwpc.2023.100928
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Background Few studies have examined effectiveness of COVID-19 vaccines against COVID-19 and all-cause mortality across different pandemic periods in 2022. Methods We used linked whole-of-population data from the 2021 Australian Census, Australian Immunisation Register, death registrations and other national datasets including migration data. Among 3.8 million adults aged 65+ years and >170,000 aged care residents, we used survival analysis to estimate vaccine effectiveness (VE) against COVID-19 specific mortality and all-cause mortality, by vaccine dose and time since receipt, adjusted for age, sex and other factors. We also estimated absolute COVID-19 mortality rates. Findings From January-May 2022 (Omicron BA.1/2), 3250 COVID-19 deaths occurred; from June-November (Omicron BA.4/5) 3185 COVID-19 deaths occurred. During January-May, VE of a 3rd COVID-19 vaccine dose within 3 months was 93% (95% CI 93-94%) whilst VE of a 2nd dose >6 months since receipt was 34% (26-42%). During June-November, VE of a 4th COVID-19 vaccine dose within 3 months was 84% (82-86%) whilst VE of a 3rd dose >6 months since receipt was 56% (50-62%). VE estimates for aged care residents were similar, but absolute risk reductions were substantially greater. During June-November 2022, for all-cause mortality, VE of a 4th dose within 3 months was 58% (56-59%) whilst VE of a 3rd dose >6 months since receipt was 19% (16-22%). Interpretations COVID-19 vaccination is highly effective against COVID-19 mortality among older adults although effectiveness wanes with time since the last dose. Our findings emphasise the importance of continuing to administer booster doses, particularly to those at highest risk.
引用
收藏
页数:13
相关论文
共 50 条
  • [41] Racial and Ethnic Disparities in Age-Specific All-Cause Mortality During the COVID-19 Pandemic
    Faust, Jeremy Samuel
    Renton, Benjamin
    Bongiovanni, Tasce
    Chen, Alexander Junxiang
    Sheares, Karen Dorsey
    Du, Chengan
    Essien, Utibe R.
    Fuentes-Afflick, Elena
    Haywood, Trent
    Khera, Rohan
    King, Terris
    Li, Shu-Xia
    Lin, Zhenqiu
    Lu, Yuan
    Marshall, Andrew D. A.
    Ndumele, Chima D.
    Opara, Ijeoma
    Loarte-Rodriguez, Tina
    Sawano, Mitsuaki
    Taparra, Kekoa
    Taylor, Herman A.
    Watson, Karol E.
    Yancy, Clyde W.
    Krumholz, Harlan M.
    JAMA NETWORK OPEN, 2024, 7 (10)
  • [42] A Critical Analysis of All-Cause Deaths during COVID-19 Vaccination in an Italian Province
    Alessandria, Marco
    Malatesta, Giovanni M.
    Berrino, Franco
    Donzelli, Alberto
    MICROORGANISMS, 2024, 12 (07)
  • [43] Assessment of COVID-19 vaccination effectiveness
    Stoczynska-Fidelus, Ewelina
    Rieske, Piotr
    ALERGOLOGIA POLSKA-POLISH JOURNAL OF ALLERGOLOGY, 2022, 9 (01) : 1 - 13
  • [44] COMPARISON OF ALL-CAUSE-MORTALITY BEFORE AND AFTER COVID-19 VACCINATION IN A HEMODIALYSIS
    Yavari, Vahideh
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2022, 37 : I593 - I593
  • [45] Risk of COVID-19 in pediatric population and the effects of COVID-19 vaccination: A retrospective cohort study
    Corona, Kassandra
    Saripada, Janisah Amirah I.
    Wermine, Kendall
    Seavey, Sydney
    Figueira, Bibiana Toro
    LaHaye, Joshua J.
    Yoshiyasu, Yuki
    Daram, Shiva
    McKinnon, Brian
    AURIS NASUS LARYNX, 2024, 51 (03) : 481 - 487
  • [46] All-cause and cause-specific mortality among people with and without intellectual disabilities during the COVID-19 pandemic in the Netherlands: a population-based cohort study
    Cuypers, Maarten
    Koks-Leensen, Monique C. J.
    Schalk, Bianca W. M.
    Bakker-van Gijssel, Esther J.
    Leusink, Geraline L.
    Naaldenberg, Jenneken
    LANCET PUBLIC HEALTH, 2023, 8 (05): : E356 - E363
  • [47] All-Cause Maternal Mortality in the US Before vs During the COVID-19 Pandemic
    Thoma, Marie E.
    Declercq, Eugene R.
    JAMA NETWORK OPEN, 2022, 5 (06)
  • [48] Characterizing all-cause excess mortality patterns during COVID-19 pandemic in Mexico
    Dahal, Sushma
    Banda, Juan M.
    Bento, Ana I.
    Mizumoto, Kenji
    Chowell, Gerardo
    BMC INFECTIOUS DISEASES, 2021, 21 (01)
  • [49] A prognostic model of all-cause mortality at 30 days in patients with cancer and COVID-19
    Halabi, S.
    Luo, B.
    Dzimitrowicz, H.
    Hwang, C.
    Wise-Draper, T. M.
    Labaki, C.
    Mckay, R. R.
    Ruiz, E.
    Rangel-Escareno, C.
    Farmakiotis, D.
    Griffiths, E. A.
    Jani, C. T.
    Accordino, M.
    Friese, C.
    Wulff-Burchfield, E.
    Puc, M.
    Yu, P.
    Topaloglu, U.
    Mishra, S.
    Warner, J.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S771 - S772
  • [50] Disparities in All-Cause Mortality Beyond the Acute Phase of the COVID-19 Pandemic in the US
    Berry, Kaitlyn M.
    Stokes, Andrew C.
    Morris, Keeley J.
    Raquib, Rafeya V.
    Wrigley-Field, Elizabeth
    JAMA NETWORK OPEN, 2024, 7 (02) : E2356869